The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2003

Filed:

Aug. 13, 2001
Applicant:
Inventors:

Kyosuke Haze, Shizuoka, JP;

Hiderou Yoshida, Shiga, JP;

Kazutoshi Mori, Kyoto, JP;

Hideki Yanagi, Tekarazuka, JP;

Takashi Yura, Kyoto, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 1/512 ;
U.S. Cl.
CPC ...
C12N 1/512 ;
Abstract

A factor capable of efficiently regulating expression of an endoplasmic chaperone gene, a nucleic acid encoding it, a complementary strand nucleic acid thereof, a method for regulating expression of an endoplasmic reticulum chaperone gene, and a method for expressing a foreign gene is provided. The endoplasmic reticulum stress transcription factor is capable of regulating transcription-inducing activity, wherein the transcription-inducing activity is exhibited by an element having the nucleotide sequence shown in SEQ ID NO:1 or an element having a nucleotide sequence resulting from substitution of 1 to 3 bases with other bases in the nucleotide sequence as shown in SEQ ID NO:1. A method for controlling expression of an endoplasmic reticulum chaperone, comprising expressing the factor; a method for expressing a foreign protein, comprising positively regulating expression of an endoplasmic reticulum chaperone gene by the method for controlling expression; and a nucleic acid encoding activated form of ATF6, activated form of CREB-RP, suppressive form of ATF6, or suppressive form of CREB-RP, or the complementary strand thereto are also provided. It is expected to be applied to treatment or prophylaxis of cancers, arteriosclerosis, cystic fibrosis, ischemic diseases, wounds or ulcers.


Find Patent Forward Citations

Loading…